A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

SIMPLE SUMMARY: Improvement in melanoma patients with metastatic disease is needed to better assess immunotherapies. Lactate dehydrogenase (LDH) is currently an accepted biomarker for stage IV, but it has limited utility for stage III melanoma patients. Thus, finding biomarkers for metastatic melano...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Autores principales: Bustos, Matias A., Gross, Rebecca, Rahimzadeh, Negin, Cole, Hunter, Tran, Linh T., Tran, Kevin D., Takeshima, Ling, Stern, Stacey L., O’Day, Steven, Hoon, Dave S. B.
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7696545/
https://ncbi.nlm.nih.gov/pubmed/33202891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113361
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares